Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: A phase I study

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1230-1233

  Keung, Anther C F ^a   Owens Jr , Robert C ^b,c   Eller, Mark G ^a   Weir, Scott J ^a   Nicolau, David P ^d   Nightingale, Charles H ^d  

^a SANOFI   (France)

^b MAINE MEDICAL CENTER   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFAPENTINE; DRUG METABOLITE; RIFAPENTINE; UNCLASSIFIED DRUG;

ADULT; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIPID DIET; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0032908238     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1230     Document Type: Article

References (16)

1. Birmingham, A., J. Coleman, M. L. E. Orme, B. K. Park, N. J. Pearson, A. H. Short, and P. J. Southgate. 1978. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br. J. Clin. Pharmacol. 6:455P-456P.
2. Buniva, G., D. Sassella, and G. M. Frigo. 1983. Pharmacokinetics of rifapentine in man, abstr. 111, p. 29-33. In Proceedings of the 12th International Congress of Chemotherapy.
3. Centers for Disease Control and Prevention. 1992. 1993 Revised CDC HIV classification system and expanded AIDS surveillance definition for adolescents and adults. Morbid. Mortal. Weekly Rep. 41(RR-17):1-19.
4. Chan, S. L., W. W. Yew, J. H. D. Porter, K. P. W. J. McAdam, B. W. Allen, and J. M. Dickinson. 1994. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int. J. Antimicrob. Agents 3:267-274.
5. Dickinson, J. M., and D. A. Mitchison. 1987. In vitro activity of selected rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 68:177-182.
6. Heifets, L. B., P. J. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
7. Keung, A. C.-F., M. G. Eller, K. A. McKenzie, and S. J. Weir. Single and multiple dose pharmacokinetics of rifapentine and its active metabolite 25-desacetyl-rifapentine in man. Submitted for publication.
8. Keung, A. C.-F., T. D. Miller, V. I. Green, M. Ames, M. G. Eller, and S. J. Weir. 1995. Bioavailability and food effect study of rifapentine in healthy adults. Pharm. Res. 12(Suppl.):S419.
9. Mor, N., B. Simon, N. Mezo, and L. Heifets. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
10. Owens, R. C., Jr., A. C.-F. Keung, S. Gardner, M. G. Eller, S. J. Weir, D. P. Nicolau, and C. H. Nightingale. 1997. Pharmacokinetic and food effect evaluation of rifapentine in subjects seropositive for the human immunodeficiency virus, abstr. A-2, p. 1. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Reith, K., A. C.-F. Keung, P. C. Toren, M. G. Eller, L. Cheng, and S. J. Weir. Mass balance and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos., in press.
12. Truffot, C., R. Bismuth, C. Boval, et al. 1982. The in vitro and in vivo experimental activity of cyclopentyl rifamycin (DL-473) on mycobacterium tuberculosis. Current chemotherapy and immunotherapy, abstr. 693, p. 172. In Proceedings of the 12th International Congress of Chemotherapy.
13. Wehrll, W. 1983. Rifampin: mechanisms of action and resistance. Rev. Infect. Dis. 5(Suppl. 3):S407-S411.
14. Yan, B., N. X, L. Zhu, F. Zhang, et al. 1987. Absorption and elimination of cyclopentyl-rifamycin in human subjects. Chin. J. Tuberc. Respir. Dis. 10: 267-268.
15. Zhang, Q., Y. Cao, and Y. Zhang. 1994. Clinical pharmacokinetic study on rifapentine. Chin. J. Antibiot. 19:456-458.
16. Zheng, C., L. Yi, and Z. Huiyan. 1987. Pharmacokinetics of domestic rifapentine in patients with acute pulmonary infections. Chin. J. Antibiot. 12:333-336.